<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-section" /><meta name="keywords" content="Anthracyclines; Doxorubicin; Leukaemia: acute; Epirubicin; Idarubicin; Daunorubicin; Mitoxantrone; Bleomycin; Dactinomycin; Mitomycin" /><meta name="IX" content="Anthracyclines; Doxorubicin; Leukaemia: acute; Epirubicin; Idarubicin; Daunorubicin; Mitoxantrone; Bleomycin; Dactinomycin; Mitomycin" /><title>8.1.2 Anthracyclines and other cytotoxic antibiotics: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="4704.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="4704.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=4704.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2075.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="4676.htm">8.1 Cytotoxic drugs</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="4699.htm" title="Previous: TREOSULFAN">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="4707.htm" title="Next: BLEOMYCIN">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_4704">8.1.2 Anthracyclines and other cytotoxic antibiotics</h1><?highlighter on?><div id="pC" class="jN"><div><p>Drugs in this group are widely used. <span id="_4704.1">Many cytotoxic <span>antibiotics</span> act as radiomimetics and simultaneous
use of radiotherapy should be <b>avoided</b> because it may markedly increased toxicity.</span></p><p><b><span>Daunorubicin</span></b>, <b>doxorubicin</b>, <b>epirubicin</b> and <b>idarubicin</b> are anthracycline <span>antibiotics</span>. Mitoxantrone is an anthracycline derivative.</p><div id="_1199883028887"><p><b>Doxorubicin</b> is
used to treat the acute leukaemias, Hodgkin’s and non-Hodgkin’s lymphomas, paediatric
malignancies, and some solid tumours including breast cancer. It is
given by injection into a fast-running infusion, commonly at 21-day
intervals. <span id="_4704.2">Extravasation can cause severe tissue necrosis. Doxorubicin
is largely excreted in the bile and an elevated bilirubin
concentration is an indication for reducing the dose. Diarrhoea, dehydration, and red coloration of the urine can commonly
occur, and renal damage has been reported. Supraventricular tachycardia
related to drug administration is an uncommon complication.</span> <span id="_202224">Higher cumulative doses are associated with cardiomyopathy and it
is usual to limit total cumulative doses to 450 mg/m<sup>2</sup> because
symptomatic and potentially fatal heart failure is common above this
dose. Patients should be assessed before treatment by
echocardiography</span><span id="_202221">; the elderly, and those with cardiac disease, hypertension, or who have received myocardial irradiation, should
be treated cautiously. Cardiac monitoring may assist in determining
safe dosage. Caution is necessary with concomitant use
of cardiotoxic drugs, or drugs that reduce cardiac contractility.
Some evidence suggests that weekly low-dose administration may be
less cardiotoxic.</span> Doxorubicin is also given by bladder
instillation for the treatment of transitional cell carcinoma,
papillary bladder tumours and carcinoma <i>in-situ</i>. </p></div><div id="_4704.3"><p>Liposomal formulations of doxorubicin for intravenous use are
also available. They may reduce the incidence of cardiotoxicity and
lower the potential for local necrosis, but infusion reactions, sometimes
severe, may occur. Hand-foot syndrome (painful, macular  reddening
skin eruptions) occurs commonly with liposomal doxorubicin and may
be dose limiting. It can occur after 2–3 treatment cycles and may
be prevented by cooling hands and feet and avoiding socks, gloves,
or tight-fitting footwear for 4–7 days after treatment.</p></div><div class="cN"><h3 class="cBP">NICE guidance (paclitaxel, pegylated liposomal doxorubicin
and topotecan for second-line or subsequent treatment of advanced
ovarian cancer)</h3><p>See <a title="target-block: paclitaxel, doxorubicin, topotecan nice guidance" href="67743.htm#_67743.3">Platinum Compounds</a></p></div><div id="_1199883071435"><p><b>Epirubicin</b> is structurally
related to doxorubicin and clinical trials suggest that it is as effective
in the treatment of breast cancer. <span id="_4704.4">A maximum cumulative dose of
0.9–1 g/m<sup>2</sup> is recommended to help avoid cardiotoxicity</span>. Like doxorubicin it is given intravenously and by bladder instillation.
Hyperpigmentation of skin, nails, and oral mucosa, and red coloration
of the urine, may occur.</p></div><div id="_1199883355254"><p><b>Idarubicin</b> has general properties similar to those of doxorubicin; it is mostly
used in the treatment of haematological malignancies. Diarrhoea, abdominal
pain, haemorrhage, cardiac disorders, rash, and red pigmentation of
the urine are commonly reported. Skin and nail hyperpigmentation have
been reported less frequently. Idarubicin is given intravenously and
it may also be given by mouth.</p></div><div id="_1199883402989"><p><b><span>Daunorubicin</span> </b> also has general
properties similar to those of doxorubicin. It should be given by
intravenous infusion and is indicated for acute leukaemias. A liposomal
formulation for intravenous use is licensed for AIDS-related Kaposi’s
sarcoma.</p></div><div class="cN"><h3 class="cBP">Use with trastuzumab</h3><p><span id="_4704.8">Concomitant use of anthracyclines
with trastuzumab (section 8.1.5) is associated with cardiotoxicity</span>; for details, see <a title="target-block: use with anthracyclines" href="88510.htm#_1.4">Use with anthracyclines</a>.</p></div><div id="_1199883476035"><p><b>Mitoxantrone</b> is structurally related to doxorubicin; it is used for metastatic
breast cancer. Mitoxantrone is also licensed for treatment of non-Hodgkin’s
lymphoma, adult acute non-lymphocytic leukaemia, and non-resectable
primary hepatocellular carcinoma. It is given intravenously and is
well tolerated, but myelosuppression and <span id="_4704.5">dose-related cardiotoxicity occur; cardiac examinations are recommended after a cumulative dose of 160 mg/m<sup>2</sup>.</span></p></div><div id="_1199883547831"><p><b><span>Bleomycin</span></b> is given intravenously or intramuscularly
to treat metastatic germ cell cancer and, in some regimens, non-Hodgkin’s
lymphoma. It causes little bone-marrow suppression but dermatological toxicity is common and increased pigmentation
particularly affecting the flexures and subcutaneous sclerotic plaques
may occur. Mucositis is also relatively common and an association
with Raynaud’s phenomenon is reported. <span id="_4704.6">Hypersensitivity reactions manifest by chills
and fevers commonly occur a few hours after drug administration and
may be prevented by simultaneous administration of a corticosteroid,
for example <span>hydrocortisone</span> intravenously.
The principal problem associated with the use of <span>bleomycin</span> is progressive pulmonary fibrosis. This is dose-related, occurring
more commonly at cumulative doses greater than 300 000 units (see <span>Bleomycin</span>, below) and in the elderly. Basal lung crepitations or suspicious
chest X-ray changes are an indication to stop therapy with this drug. Patients who have received extensive treatment with <span>bleomycin</span> (e.g. cumulative dose more than 100 000 units—see <span>Bleomycin</span> below) may be at risk of developing respiratory
failure if a general anaesthetic is given with high inspired oxygen
concentrations. Anaesthetists should be warned of this.</span></p></div><div id="_1199883592174"><p><b><span>Dactinomycin</span> </b> is principally used to treat paediatric
cancers; it is given intravenously. Its side-effects are similar to
those of doxorubicin, except that cardiac toxicity is not a problem.</p></div><div id="_1199883630736"><p><b><span>Mitomycin</span> </b> is given intravenously to treat upper
gastro-intestinal and breast cancers and by bladder instillation for
superficial bladder tumours. <span id="_4704.7">It causes delayed bone-marrow toxicity and
therefore it is usually administered at 6-weekly intervals. Prolonged use may result in permanent bone-marrow damage.</span> It may also cause lung fibrosis and renal damage.</p></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_4707"><a href="4707.htm" title="BLEOMYCIN">BLEOMYCIN</a></li><li id="_4709"><a href="4709.htm" title="DACTINOMYCIN">DACTINOMYCIN</a></li><li id="_37025"><a href="37025.htm" title="DAUNORUBICIN">DAUNORUBICIN</a></li><li id="_4711"><a href="4711.htm" title="DOXORUBICIN HYDROCHLORIDE">DOXORUBICIN HYDROCHLORIDE</a></li><li id="_4714"><a href="4714.htm" title="EPIRUBICIN HYDROCHLORIDE">EPIRUBICIN HYDROCHLORIDE</a></li><li id="_4717"><a href="4717.htm" title="IDARUBICIN HYDROCHLORIDE">IDARUBICIN HYDROCHLORIDE</a></li><li id="_4719"><a href="4719.htm" title="MITOMYCIN">MITOMYCIN</a></li><li id="_4721"><a href="4721.htm" title="MITOXANTRONE">MITOXANTRONE</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="4699.htm">Previous: TREOSULFAN</a> | <a class="top" href="4704.htm#">Top</a> | <a accesskey="]" href="4707.htm">Next: BLEOMYCIN</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>